Institute of Physiology  
220072 Minsk, Academic St., 28

Technology for controlling the processes of activation of endogenous stem cells









Linked profile in other language
Tatiana Khrustaleva
+375 17 378 1630
The Institute of Physiology offers endogenous stem cell activation control technology to consumers under a commercial agreement with technical assistance and is looking for partners to conclude an agreement on scientific cooperation.
A technology for activating endogenous brain stem cells by physical factors has been developed and introduced into clinical practice to increase the neurotrophic potential during the restoration of impaired brain functions.

Together with neurosurgeons of the Republican Scientific and Practical Center for Neurology and Neurosurgery, a method of activating endogenous stem cells in the nasal cavity was tested in 4 patients on the basis of the City Clinical Emergency Hospital.
Advantages and Innovations
The introduction of technology into the complex of rehabilitation measures allows reducing the recovery time for patients with neurodestructive processes.
Stage of development
Field tested/evaluated (TRL8)
Funding source
State budged
IPR status
Exclusive rights
Secret know-how
Sector group

Organization information

R&D institution
Year established
NACE keywords
Q.86.90 - Other human health activities
M.72.11 - Research and experimental development on biotechnology
M.72.19 - Other research and experimental development on natural sciences and engineering
M.74.90 - Other professional, scientific and technical activities n.e.c.
Turnover (in EUR)
Already engaged in transnational cooperation
Additional comments
The Institute is a leading scientific institution coordinating physiological research in the Republic of Belarus. The institute successfully carries out fundamental and applied research aimed at developing methods for the prevention and correction of pathological conditions of hypoxic, ischemic and inflammatory origin, and develops new devices and methods for their therapeutic and prophylactic use. The main scientific activity of the divisions is currently focused on studying the mechanisms of the formation of pathological conditions of the body (primarily hypoxic and neurodestructive) and substantiating new technologies for prevention, treatment and rehabilitation. Particular attention is paid to the development of complex methods for the treatment of malignant tumors using effectors of the blockade of metabolism and high-intensity pulsed magnetic fields and methods for controlling the proliferation of tumor cells based on changes in the functional state of neuroreceptors in vitro and in vivo, as well as the development of a method for immunotherapy of patients suffering from pancreatic cancer. , using autologous dendritic cells primed with tumor antigens and elucidating new mechanisms of tumor formation, substantiation of prevention methods. Research is underway on the molecular mechanisms of proliferation, differentiation, and oncogenesis; physiological and therapeutic effect of physical factors and the development of new technologies of physiotherapy and physiotherapy equipment and experimental analysis of the positive and negative aspects of the use of nanoparticles and heterocyclic compounds in biomedical technologies. The neurophysiological bases of dysregulation of the functions of internal organs during ischemia of the nervous tissue of various origins are being studied. Works on the physiology of nutrition and sports are being carried out. Preclinical studies of drugs and nanomaterials are underway.
Languages spoken

Information about partnership

Type of partnership considered
Commercial agreement with technical assistance
Research cooperation agreement
Type and role of partner sought
Consumers interested in purchasing the technology for controlling the processes of activation of endogenous stem cells under a commercial agreement with technical assistance.

Partners interested in concluding an research cooperation agreement.
Type and size of partner sought
SME 51-250
SME 11-50
SME <= 10
R&D Institution
Views: 1317
Statistics since 12.03.2022 10:51:53